Literature DB >> 12756088

Brachytherapy: update and results.

Rodney J Ellis1, Edward Kim.   

Abstract

Prostate cancer is the most common noncutaneous malignancy and the second most common cause of cancer mortality in American men. Treatment options for these patients include radical prostatectomy, external beam radiation therapy, hormonal therapy, and prostate brachytherapy. Patients with clinically and radiographically localized disease, especially young patients with few comorbid illnesses, are good candidates for prostate brachytherapy. Prostate brachytherapy has gained widespread acceptance throughout the past two decades and data from several large series of patients are now available. This article describes current techniques, treatment issues, and clinical results of permanent seed implants.

Entities:  

Mesh:

Year:  2003        PMID: 12756088     DOI: 10.1007/s11934-003-0075-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  35 in total

1.  Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer.

Authors:  A Singh; M J Zelefsky; A Raben; D Lombardi; S A Leibel
Journal:  Int J Cancer       Date:  2000-10-20       Impact factor: 7.396

2.  Transperineal interstitial implantation of prostate cancer: a new method.

Authors:  K K Charyulu
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-09       Impact factor: 7.038

3.  Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.

Authors:  H Ragde; L J Korb; A A Elgamal; G L Grado; B S Nadir
Journal:  Cancer       Date:  2000-07-01       Impact factor: 6.860

4.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Authors:  M J Zelefsky; T Hollister; A Raben; S Matthews; K E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

5.  Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy.

Authors:  K Hu; K Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

6.  Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer.

Authors:  Steven J DiBiase; Keya Hosseinzadeh; Rao P Gullapalli; Stephen C Jacobs; Michael J Naslund; Geoffrey N Sklar; Richard B Alexander; Cedric Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

7.  Radioimmunoguided imaging of prostate cancer foci with histopathological correlation.

Authors:  R J Ellis; E Y Kim; R Conant; D B Sodee; J P Spirnak; K H Dinchman; S Beddar; B Wessels; M I Resnick; T J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-04-01       Impact factor: 7.038

8.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.

Authors:  K Wallner; J Roy; L Harrison
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-05-15       Impact factor: 7.038

9.  Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation.

Authors:  Gregory S Merrick; Wayne M Butler; Jonathan H Lief; Robert W Galbreath; Edward Adamovich
Journal:  Brachytherapy       Date:  2002       Impact factor: 2.362

10.  Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy.

Authors:  Young Kwok; Steven J DiBiase; Pradip P Amin; Michael Naslund; Geoffrey Sklar; Stephen C Jacobs
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.